Biological therapies in immune-mediated inflammatory diseases: Can biosimilars reduce access inequities?

Similar Items

• Addressing Inequality of Access to Biologics: What Is Your Role? A Patient (Advocate)’s Perspective on Biosimilars
  by: Maria M. Piggin
  Published: (2022-04-01)
• New etanercept biosimilar — expanding treatment options for immune-mediated inflammatory rheumatic diseases
  by: A. E. Karateev, et al.
  Published: (2022-12-01)
• Author's answer: biosimilar therapy for inflammatory bowel disease
  by: Federico Argüelles-Arias, et al.
  Published: (2014-01-01)
• The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy
  by: Eva Rahman Kabir, et al.
  Published: (2019-08-01)
• Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review
  by: Naazish S. Bashir, et al.
  Published: (2023-02-01)